Blood-based Shield Multi-Cancer Detection (MCD) test exhibits high specificity, clinically meaningful sensitivity and strong cancer signal of origin accuracy Results informed National Cancer Institute ...
PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough ...
InvestorsHub on MSN
Guardant Health Shares Climb on FDA Breakthrough Status for Cancer Detection Test
Guardant Health Inc. (NASDAQ:GH) saw its stock rise by 3.7% after announcing that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its Shield multi-cancer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results